MPT64 secretion as a viability-associated immunoassay readout for rapid phenotypic drug susceptibility classification of Mycobacterium tuberculosis : a proof-of-concept study
- 6 October 2026
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (11)
Abstract
Objectives: To evaluate MPT64 secretion as a viability-associated readout for rapid phenotypic drug susceptibility testing (pDST) of Mycobacterium tuberculosis. Methods: We evaluated MPT64-pDST in 130 M. tuberculosis strains: clinical isolates, WHO quality assessment strains and in vitro-selected resistant mutants (for linezolid only). We assessed the diagnostic performance of MPT64-pDST for determining susceptibility to rifampicin, isoniazid and moxifloxacin. As a secondary objective, we explored its performance for linezolid and bedaquiline. MPT64 was quantified by chemiluminescent enzyme immunoassay, and susceptibility was inferred from Log2 fold change relative to drug-free controls. Reference standards were minimum inhibitory concentration testing for rifampicin, isoniazid, linezolid and bedaquiline and MGIT-based DST for moxifloxacin. Performance was evaluated using receiver operating characteristic analysis, full-dataset Youden-optimal candidate cutoffs and 2000-iteration stratified bootstrap out-of-bag (OOB) internal validation. Results: Using drug-specific full-dataset Youden-optimal candidate cutoffs, MPT64-pDST showed high categorical agreement with reference DST, with no false-resistant classifications for rifampicin, isoniazid or moxifloxacin. Resistance-detection sensitivity was 100% for rifampicin, 98% for isoniazid and 90% for moxifloxacin, and out-of-bag bootstrap estimates were comparable to the full-dataset estimates. Exploratory analyses for linezolid demonstrated separation between susceptible and resistant mutants. The single bedaquiline-resistant isolate was clearly distinguishable from 39 bedaquiline-susceptible isolates. Conclusions: These findings provide proof of concept that the immunoassay-based MPT64-pDST can enable rapid phenotypic susceptibility classification for rifampicin, isoniazid and moxifloxacin. Further validation in larger isolate collections, including isolates with borderline phenotypes, is warranted.Keywords
Funding Information
- Japan Society for the Promotion of Science (24K11669)
- Japan Agency for Medical Research and Development (23fk0108607h)
- National Institutes of Health (5R01AI176409)
- TAUNS Laboratories, Inc
This publication has 15 references indexed in Scilit:
- Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approachNature Communications, 2024
- Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysisThe Lancet Microbe, 2024
- Association of lineage 4.2.2 of Mycobacterium tuberculosis with the 63-bp deletion variant of the mpt64 geneMicrobiology Spectrum, 2023
- A novel, rapid (within hours) culture-free diagnostic method for detecting live Mycobacterium tuberculosis with high sensitivityEBioMedicine, 2020
- Ultrasensitive enzyme-linked immunosorbent assay for the detection of MPT64 secretory antigen to evaluate Mycobacterium tuberculosis viability in sputumInternational Journal of Infectious Diseases, 2020
- Low sensitivity of the MPT64 identification test to detect lineage 5 of the Mycobacterium tuberculosis complexJournal of Medical Microbiology, 2018
- Rapid screening drug susceptibility test in tuberculosis using sandwich electrochemical immunosensorAnalytica Chimica Acta, 2018
- Susceptibility testing breakpoints forMycobacterium tuberculosiscategorize isolates with resistance mutations ingyrAas susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TBJournal of Antimicrobial Chemotherapy, 2015
- STARD 2015: an updated list of essential items for reporting diagnostic accuracy studiesBMJ, 2015
- Rapid confirmation of drug susceptibility in Mycobacterium tuberculosis using MPT 64 Ag based testAsian Pacific Journal of Tropical Disease, 2013